ACLXライブシグナル | Getagraph.comで利益を最大化

売る 108128 min ago

@ $63.29

発行日: 14 2月 2024 @ 23:30

リターン: -18.27%

前回のシグナル: 2月 13 - 03:39

前回のシグナル: 買う

リターン: -0.81 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:37):

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases...

Stats
本日の出来高	109 147
平均出来高	455 512
時価総額	2.73B
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.510 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-35.18
ATR14	$0.0740 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Ware Olivia C	Sell	9 402	Stock Option (right to buy)
2024-04-16	Ware Olivia C	Buy	9 402	Common Stock
2024-04-16	Ware Olivia C	Sell	6 790	Common Stock
2024-04-16	Ware Olivia C	Sell	2 612	Common Stock
2024-04-01	Elghandour Rami	Sell	14 919	Common Stock

INSIDER POWER
-47.09
Last 100 transactions
Buy: 1 139 480 \| Sell: 3 755 187

ボリューム相関

長: -0.14 (neutral)

短: 0.47 (neutral)

Signal:(53.764) Neutral

Arcellx, Inc. 相関

10 最も正の相関
RMRM	0.953
MOTNU	0.932
LIAN	0.911
NYMX	0.911
SDIG	0.909
AGYS	0.909
GLMD	0.908
PSCH	0.908
ICON	0.906
PSCC	0.906

10 最も負の相関
ATHN	-0.935
NXTC	-0.932
PTRA	-0.932
IOAC	-0.932
LITE	-0.93
GTLB	-0.928
CWBR	-0.924
AXDX	-0.921
TSLA	-0.92
LGHL	-0.917

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Arcellx, Inc. 相関 - 通貨/商品

0.11
( neutral )

0.20
( neutral )

0.00
( neutral )

0.15
( neutral )

-0.75
( moderate negative )

-0.35
( neutral )

Arcellx, Inc. 財務諸表

Annual	2023
収益:	$110.32M
総利益:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2023
収益:	$110.32M
総利益:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2022
収益:	$0
総利益:	$-2.22M (0.00 %)
EPS:	$-4.22

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.02

Financial Reports:

No articles found.

Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.